Details checkedClinical trial listing onlyCheckedregistry

Chang Gung Topiramate Adjunct Study for Sudden Sensorineural Hearing Loss

Also known as: Topiramate, Systemic Steroids, The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss, NCT05403229

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Unknown

Target Gene

—

Route / Mode

Oral topiramate adjunct to systemic/intratympanic steroid therapy

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Taiwan

Population

adult, sudden, sensorineural

Trial IDs

Mechanism

Phase 2 institution-led trial evaluating oral topiramate added to standard systemic/intratympanic steroid therapy for sudden sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Collapsed the generated systemic-steroids comparator row into this topiramate adjunct study. Systemic steroids are standard treatment in both arms and should not appear as a separate HearScape pipeline program from this trial.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT05403229

Open

Key Events

2022-10-17

Registry lists actual study start for topiramate adjunct trial in sudden sensorineural hearing loss

Clinical Trials (1)

NCT05403229

Data Checks